(24/7 MARKET NEWS) – NexImmune, Inc. (Nasdaq: NEXI) stated, this morning, that new positive, preclinical data will be presented in an abstract titled “Prior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy” at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place on February 15-19, 2023 in Orlando, Florida, highlighting how Tumor Associated Antigen (TAA)-specific AIM ACT CD8 T cells are superior to polyclonal peripheral blood CD4 T cells, naive CD8 T cells, and bulk CD8 T cells as effectors of BiTE-mediated killing in vivo.
NexImmune is at $0.51, up $0.10 (+24.37%), on 400 thousand premarket shares.
Its 52-week trading range is $ 0.1947 to $4.91. It’s cleared over three months’ worth of resistance levels and, if it can break through the $0.78 resistance, on strong trading volume, it looks like it wants to challenge the $1.25 level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
